<ul><li>Systematix Institutional Equities recommends 'sell' on Dr. Reddy's stock after Q3 results.</li><li>The brokerage expects the new business avenues of Dr. Reddy's to take a few years before contributing profitably.</li><li>Dr. Reddy's Q3 revenue was inline, but Ebitda and net earnings were lower than expected.</li><li>Dr. Reddy's SG&A and research spend has increased nearly 50% over the past two years.</li></ul>

Dr. Reddy’s: Systematix Recommends 'Sell' On The Stock After Q3 Results — Here's Why

Discover more